StreetInsider.com News Articles

AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts

Mon, 22 Jun 2026 08:00:00 -0400

Newly Constructed Phase 2 now 100% Leased

Further Solidifies Innovation Park as Boston's Premier Advanced Manufacturing Destination

BOSTON, June 22, 2026 /PRNewswire/ -- IQHQ, Inc. today announced that AdvanCell has signed a long-term ~128,000 square foot lease for the entire 1 Corporate Drive building at Innovation Park, IQHQ's premier life science and advanced manufacturing campus in Andover, Massachusetts. The transaction is one of the largest life science leases in Greater Boston this year and brings the newly constructed Phase 2 of Innovation Park to 100%

AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts

Mon, 22 Jun 2026 08:00:00 -0400

Newly Constructed Phase 2 now 100% Leased

Further Solidifies Innovation Park as Boston's Premier Advanced Manufacturing Destination

AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts

Mon, 22 Jun 2026 08:00:00 -0400

Newly Constructed Phase 2 now 100% Leased

Further Solidifies Innovation Park as Boston's Premier Advanced Manufacturing Destination

AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts

Mon, 22 Jun 2026 08:00:00 -0400

Newly Constructed Phase 2 now 100% Leased

Further Solidifies Innovation Park as Boston's Premier Advanced Manufacturing Destination

AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts

Mon, 22 Jun 2026 08:00:00 -0400

Newly Constructed Phase 2 now 100% Leased

Further Solidifies Innovation Park as Boston's Premier Advanced Manufacturing Destination

AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts

Mon, 22 Jun 2026 08:00:00 -0400

Newly Constructed Phase 2 now 100% Leased

Further Solidifies Innovation Park as Boston's Premier Advanced Manufacturing Destination

AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts

Mon, 22 Jun 2026 08:00:00 -0400

Newly Constructed Phase 2 now 100% Leased

Further Solidifies Innovation Park as Boston's Premier Advanced Manufacturing Destination

AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts

Mon, 22 Jun 2026 08:00:00 -0400

Newly Constructed Phase 2 now 100% Leased

Further Solidifies Innovation Park as Boston's Premier Advanced Manufacturing Destination

AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts

Mon, 22 Jun 2026 08:00:00 -0400

Newly Constructed Phase 2 now 100% Leased

Further Solidifies Innovation Park as Boston's Premier Advanced Manufacturing Destination

AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts

Mon, 22 Jun 2026 08:00:00 -0400

Newly Constructed Phase 2 now 100% Leased

Further Solidifies Innovation Park as Boston's Premier Advanced Manufacturing Destination

AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts

Mon, 22 Jun 2026 08:00:00 -0400

Newly Constructed Phase 2 now 100% Leased

Further Solidifies Innovation Park as Boston's Premier Advanced Manufacturing Destination

AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts

Mon, 22 Jun 2026 08:00:00 -0400

Newly Constructed Phase 2 now 100% Leased

Further Solidifies Innovation Park as Boston's Premier Advanced Manufacturing Destination

AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts

Mon, 22 Jun 2026 08:00:00 -0400

Newly Constructed Phase 2 now 100% Leased

Further Solidifies Innovation Park as Boston's Premier Advanced Manufacturing Destination

AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts

Mon, 22 Jun 2026 08:00:00 -0400

Newly Constructed Phase 2 now 100% Leased

Further Solidifies Innovation Park as Boston's Premier Advanced Manufacturing Destination

Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference

Thu, 28 May 2026 16:20:00 -0400

SOMERVILLE, Mass., May 28, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ: GENB) today announced that it intends to participate in the Goldman Sachs Global Healthcare Conference on Monday, June 8, 2026.

Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference

Thu, 28 May 2026 16:20:00 -0400

Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference

Thu, 28 May 2026 16:20:00 -0400

Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference

Thu, 28 May 2026 16:20:00 -0400

Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference

Thu, 28 May 2026 16:20:00 -0400

Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference

Thu, 28 May 2026 16:20:00 -0400

Generate Biomedicines (GENB) PT Raised to $22 at Morgan Stanley

Thu, 14 May 2026 08:52:55 -0400

Morgan Stanley analyst Sean Laaman raised the price target on Generate Biomedicines (NASDAQ: GENB) to $22.00 (from $20.00) while maintaining a Overweight rating.

Generate Biomedicines (GENB) PT Raised to $25 at H.C. Wainwright

Fri, 08 May 2026 07:00:35 -0400

H.C. Wainwright analyst Mitchell Kapoor raised the price target on Generate Biomedicines (NASDAQ: GENB) to $25.00 (from $16.00) while maintaining a Buy rating.

Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update

Thu, 07 May 2026 06:16:00 -0400

SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance
Clinical trial sites activated for GB-4362 (MMAE neutralizer); first patient dosing is expected in mid-2026; program has received FDA Fast Track designation
First patient dosing is expected in the second half of 2026 for GB-5267 (MUC16 armored CAR T); developed in collaboration with Roswell Park Comprehensive Cancer Center
Approximately $516.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026

SOMERVILLE, Mass., May 7, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ: GENB) ("Generate") today reported financial results for the first quarter ended March

Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update

Thu, 07 May 2026 06:16:00 -0400

SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance
Clinical trial sites activated for GB-4362 (MMAE neutralizer); first patient dosing is expected in mid-2026; program has received FDA Fast Track designation
First patient dosing is expected in the second half of 2026 for GB-5267 (MUC16 armored CAR T); developed in collaboration with Roswell Park Comprehensive Cancer Center
Approximately $516.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026

SOMERVILLE, Mass., May 7, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ: GENB) ("Generate") today reported financial results for the first quarter ended March

Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update

Thu, 07 May 2026 06:16:00 -0400

SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance
Clinical trial sites activated for GB-4362 (MMAE neutralizer); first patient dosing is expected in mid-2026; program has received FDA Fast Track designation
First patient dosing is expected in the second half of 2026 for GB-5267 (MUC16 armored CAR T); developed in collaboration with Roswell Park Comprehensive Cancer Center
Approximately $516.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026

SOMERVILLE, Mass., May 7, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ: GENB) ("Generate") today reported financial results for the first quarter ended March